# Reconstructing Menopausal Hormone Therapy Guidelines
## From Palliative Symptom Management to Age-Related Endocrine Insufficiency Disease Prevention

[![DOI](https://zenodo.org/badge/DOI/10.5281/zenodo.17775748.svg)](https://doi.org/10.5281/zenodo.17775748)


---

## üö® Critical Update: FDA Reversal & Institutional Non-Response

**November 10, 2025**: The FDA formally reversed 23 years of restrictive menopausal hormone therapy (MHT) guidance, removing black-box warnings and acknowledging that Women's Health Initiative evidence does not apply to modern formulations.

**December 2025**: Major professional organizations (ACOG, NAMS, Endocrine Society) have **not announced guideline reviews** despite this regulatory reversal.

This repository documents why comprehensive guideline reconstruction is institutional necessity, not optional refinement.

---

## üìã Executive Summary

### The Problem

- **WHI findings apply only to outdated formulations** (conjugated equine estrogen + medroxyprogesterone acetate)
- **Modern bioidentical formulations** (transdermal estradiol + micronized progesterone) have fundamentally different pharmacology
- **15-20 years of registry data** consistently show no harm signals from modern formulations
- **Professional organizations maintain restrictive guidelines** despite FDA acknowledgment and contradictory evidence

### The Evidence

- **Cardiovascular benefits**: 30-50% reduction in mortality with early initiation (DOPS, ELITE trials)
- **Bone preservation**: 40% reduction in vertebral fractures, 25% reduction in hip fractures
- **Metabolic protection**: 20-30% reduction in type 2 diabetes incidence
- **Cognitive preservation**: Reduced Alzheimer's risk with early initiation
- **Safety profile**: No increased breast cancer risk with transdermal E2 + micronized P4 (E3N-EPIC, Cold et al.)

### The Institutional Failure

This analysis applies the **Evidence-Selective Medicine (ESM) framework** to document six institutional mechanisms perpetuating guideline obsolescence:

1. **Methodological asymmetry**: Unequal scrutiny of paradigm-challenging vs. paradigm-confirming evidence
2. **Reporting asymmetry**: WHI statistical misrepresentation (p=0.05 with CI crossing 1.0)
3. **Category error**: Extrapolating findings from specific formulations to entire therapeutic class
4. **Semantic obfuscation**: Terminology that obscures mechanistic distinctions
5. **Institutional commitment architecture**: Organizations prioritizing liability management over patient welfare
6. **Ethical compartmentalization**: Informed consent barriers through categorical restrictions

[**Learn about the ESM Framework ‚Üí**](https://github.com/YOUR-USERNAME/evidence-selective-medicine)

---

## üìö Repository Contents

### Core Analysis

- **[Full Article](full-article/)**: Complete paradigm reconstruction document
  - Main document (PDF and Markdown)
  - Supplementary materials
  - References and citations


---

## üîë Key Findings

### 1. The Formulation Category Error

WHI tested **oral conjugated equine estrogen + medroxyprogesterone acetate** (Premarin/Prempro):
- Extensive first-pass hepatic metabolism ‚Üí increased VTE risk
- Synthetic progestin with proliferative effects ‚Üí increased breast cancer risk

Modern MHT uses **transdermal 17Œ≤-estradiol + micronized progesterone**:
- Bypasses hepatic metabolism ‚Üí no VTE increase
- Bioidentical progesterone with neutral/protective effects ‚Üí no breast cancer increase

**Extrapolating WHI findings to modern formulations violates basic pharmacological principles.**

### 2. Evidence Maturation Without Institutional Response

**Evidence timeline:**
- 2008: E3N-EPIC demonstrates formulation-specific breast cancer risk (n=98,995)
- 2012: DOPS shows 52% cardiovascular mortality reduction (16-year follow-up)
- 2013: KEEPS demonstrates safety of modern formulations (zero VTE events)
- 2016: ELITE proves atherosclerosis prevention with early initiation
- 2022: Cold et al. shows no late breast cancer recurrence (15.2-year follow-up)
- 2024: Baik meta-analysis demonstrates benefits even with late-life initiation

**Guideline response:**
- No substantive revision
- Continued "lowest dose, shortest duration" restrictions
- No formulation-specific guidance

**Gap between evidence maturation and institutional acknowledgment: 9-17 years**

### 3. Legal Standard Evolution

**2024 Restatement (Third) of Torts: Medical Malpractice** fundamentally redefined standard of care:

**Old standard**: Conformity with professional custom/guidelines = complete defense

**New standard**: Conduct must align with contemporary scientific evidence

**Implication**: Guideline adherence no longer provides automatic legal protection; evidence-based practice is now more legally defensible

### 4. The Reclassification Opportunity

**ICD-11 U.S. adoption (projected next few years)** creates critical window:

**Current classification**: Menopause = genitourinary/reproductive disorder (N95)
- Frames treatment as symptom management
- Positions MHT as optional/elective
- Limits insurance coverage

**Proposed reclassification**: Menopause = age-related endocrine insufficiency (under Chapter 5)
- Frames treatment as disease prevention
- Positions MHT as medically necessary
- Expands insurance coverage
- Aligns with endocrinological principles

**This classification choice determines clinical guidance orientation for decades.**

---

## üìä Evidence Summary Tables

### Modern MHT Safety Profile

| Outcome | Effect Size | Evidence Quality |
|---------|-------------|------------------|
| VTE (transdermal) | No increase | Multiple RCTs + registries |
| Breast cancer (E2+P4) | No increase | E3N-EPIC, Cold et al. |
| Cardiovascular mortality | 30-50% reduction | DOPS, meta-analyses |
| Hip fracture | 25% reduction | WHI, registries |
| Type 2 diabetes | 20-30% reduction | Long-term follow-up |
| Alzheimer's risk | 35% reduction | Multiple cohorts |

### Formulation Comparison

| Parameter | WHI (CEE/MPA) | Modern (E2/P4) |
|-----------|---------------|----------------|
| Estrogen type | Conjugated equine | Bioidentical 17Œ≤-estradiol |
| Delivery route | Oral | Transdermal |
| Hepatic metabolism | Extensive | Bypassed |
| VTE risk | Increased (HR 1.8) | No increase |
| Breast proliferation | Increased (MPA) | Neutral/protective (P4) |

---

## üî¨ Theoretical Framework

This analysis applies the **Evidence-Selective Medicine (ESM)** framework to understand institutional perpetuation of obsolete guidelines.

### Six Levels of Institutional Entrenchment

**Level 1 - Methodological Asymmetry**: Different evidentiary standards applied to paradigm-challenging vs. paradigm-supporting evidence

**Level 2 - Reporting Asymmetry**: Statistical manipulation and architectural suppression (WHI p=0.05 with CI crossing 1.0 reported as definitive harm)

**Level 3 - Category Error**: Inappropriate extrapolation across non-equivalent formulations

**Level 4 - Semantic Obfuscation**: Terminology obscuring mechanistic distinctions ("progestin" collapsing bioidentical and synthetic compounds)

**Level 5 - Institutional Commitment Architecture**: Organizations prioritizing liability management and reputational protection over evidence integration

**Level 6 - Ethical Compartmentalization**: Informed consent principles applied selectively, categorical restrictions preventing patient autonomy

[**Full ESM framework documentation ‚Üí**](https://github.com/dolomuse/evidence-selective-medicine)

---

## üéØ What This Repository Provides

### For Immediate Action

‚úÖ **Evidence-based informed consent templates** for clinical use
‚úÖ **Legal defensibility frameworks** under 2024 Restatement standard
‚úÖ **Patient education materials** for autonomous decision-making
‚úÖ **Prescribing guidelines** for modern bioidentical formulations

### For Strategic Reform

‚úÖ **Comprehensive evidence synthesis** documenting guideline failures
‚úÖ **Institutional mechanism analysis** explaining persistence
‚úÖ **Policy leverage points** (ICD-11, FDA action, legal evolution)
‚úÖ **Reform tracking** documenting progress toward reconstruction

### For Research Community

‚úÖ **Novel theoretical framework** (ESM) applicable to other medical domains
‚úÖ **Methodological analysis** of evidence evaluation asymmetries
‚úÖ **Future research directions** moving beyond obsolete equipoise
‚úÖ **International comparison** revealing U.S. exceptionalism


---

## ü§ù Contributing

This repository welcomes community contributions:

### How to Contribute

1. **Evidence updates**: New studies, registry data, trial results
2. **State-specific legal analysis**: 2024 Restatement adoption tracking
3. **Clinical implementation experiences**: Real-world evidence-based practice
4. **Patient testimonials**: Documented harm from restrictive guidelines
5. **International comparisons**: Guidelines from other countries
6. **Media coverage tracking**: Documentation of public discourse

### Contribution Guidelines

- **Evidence-based only**: All claims must be supported by citations
- **Respectful discourse**: Focus on institutional mechanisms, not personal attacks
- **Constructive**: Identify problems AND propose solutions
- **Attribution**: Credit sources appropriately
- **Accuracy**: Fact-check before submitting

**To contribute**: Open an Issue or submit a Pull Request

---

## üì¢ Derivative Works Encouraged

This analysis is comprehensive but may be too detailed for some audiences. You are explicitly encouraged to:

- ‚úÖ Create condensed versions for specific audiences
- ‚úÖ Translate into other languages
- ‚úÖ Develop state-specific legal analyses
- ‚úÖ Build data visualizations
- ‚úÖ Write patient-friendly summaries
- ‚úÖ Create clinical implementation guides
- ‚úÖ Adapt for specialty-specific contexts (oncology, cardiology, etc.)

**Requirements**: 
- Cite this repository
- Maintain intellectual honesty
- Share derivative works openly

**License**: Creative Commons Attribution 4.0 International (CC BY 4.0)

---

## üìû Contact & Media

**Author**: Dolores Catherino, M.S. (Retired Physician Assistant)

**For media inquiries**: [Create email address or contact form]

**Academic citations**:
```
Catherino, D. (2025). Reconstructing Menopausal Hormone Therapy Guidelines: 
From Palliative Symptom Management to Age-Related Endocrine Insufficiency 
Disease Prevention. GitHub repository. 
https://github.com/YOUR-USERNAME/mht-guideline-reconstruction
DOI: [Your Zenodo DOI]
```

**Related work**:
- Evidence-Selective Medicine Framework: https://github.com/dolomuse/evidence-selective-medicine
- Zenodo archive: [(https://zenodo.org/records/17775748)]
- Figshare archive: [(https://figshare.com/articles/dataset/Reconstructing_Menopausal_Hormone_Therapy_Guidelines_From_Palliative_Symptom_Management_to_Age-Related_Endocrine_Insu_ciency_Disease_Prevention/30753338?file=60009308)]
- ORCID profile: [(https://orcid.org/0009-0000-6980-3512)]

---

## ‚≠ê Star This Repository

If you find this work valuable:
- ‚≠ê **Star this repository** to bookmark and show support
- üëÅÔ∏è **Watch** for updates as guideline reform progresses
- üîÄ **Fork** to create derivative works
- üì¢ **Share** with clinicians, patients, researchers, journalists, policy makers

---

## üìÖ Last Updated

This repository is actively maintained. Last update: [Current Date]

**Major updates tracked in**: [Reform Timeline](reform-tracking/timeline.md)

---

## üìú License

This work is licensed under [Creative Commons Attribution 4.0 International License](LICENSE).

You are free to:
- **Share**: Copy and redistribute in any medium or format
- **Adapt**: Remix, transform, and build upon the material

Under these terms:
- **Attribution**: Must give appropriate credit
- **No additional restrictions**: Cannot apply legal terms or technological measures that legally restrict others from doing anything the license permits

---

## üôè Acknowledgments

This work stands on the shoulders of:
- Researchers who generated the evidence (ELITE, KEEPS, DOPS, E3N-EPIC, and many others)
- Clinicians who practiced evidence-based medicine despite institutional pressure
- Patients who demanded better than restrictive guidelines offered
- FDA leadership who acknowledged institutional failure (November 2025)
- The Evidence-Selective Medicine framework development

---

**The time for guideline reconstruction is now. The evidence is sufficient. The institutional moment is ripe. The legal protection exists. The reformation is beginning.**

**Join us.**
```

5. **Save the file** (Ctrl+S or Cmd+S)

---

### File 2: LICENSE

1. **Create new file** in root directory: `LICENSE`
2. **Paste this Creative Commons license**:
```
Creative Commons Attribution 4.0 International License (CC BY 4.0)

Copyright (c) 2025 Dolores Catherino

You are free to:
- Share: copy and redistribute the material in any medium or format
- Adapt: remix, transform, and build upon the material for any purpose, even commercially

Under the following terms:
- Attribution: You must give appropriate credit, provide a link to the license, and indicate if changes were made.

Full license text: https://creativecommons.org/licenses/by/4.0/legalcode
